PMID- 26807234
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220317
IS  - 2049-9450 (Print)
IS  - 2049-9469 (Electronic)
IS  - 2049-9450 (Linking)
VI  - 3
IP  - 6
DP  - 2015 Nov
TI  - Clinical implications of human leukocyte antigen class I expression in 
      endometrial cancer.
PG  - 1285-1290
AB  - Decreased expression of human leukocyte antigen (HLA) class I molecules, which is 
      found in several types of cancer, is associated with worse clinical prognosis in 
      cancer patients. The present study was undertaken to investigate the association 
      of immunohistochemical HLA class I expression patterns with clinicopathological 
      factors and prognosis in 96 endometrial cancer patients. HLA class I is composed 
      of a heavy chain (HC-10) and a beta2-microglobulin (beta2-m) light chain. The HLA class 
      I expression patterns were classified as positive when both HC-10 and beta2-m were 
      strongly stained and negative in all other cases. The negative staining pattern 
      was associated with advanced International Federation of Gynecology and 
      Obstetrics stage (P<0.001), lymphovascular space involvement (LVSI) (P=0.003) and 
      lymph node metastasis (P=0.005). Moreover, these cases exhibited worse 
      progression-free survival (PFS) and overall survival (OS) rates compared with 
      positive cases (P=0.005 and P=0.014, respectively). However, the multivariate 
      analysis did not identify HLA class I expression as an independent predictive 
      factor for PFS and OS. In conclusion, HLA class I expression may be useful for 
      predicting postoperative outcome in endometrial cancer, as well as well-known 
      predictive prognostic factors, such as lymph node metastasis and LVSI.
FAU - Yakabe, Kazuyuki
AU  - Yakabe K
AD  - Department of Obstetrics and Gynecology, Graduate School of Medicine, Yamaguchi 
      University, Ube, Yamaguchi 755-8505, Japan.
FAU - Murakami, Akihiro
AU  - Murakami A
AD  - Department of Obstetrics and Gynecology, Graduate School of Medicine, Yamaguchi 
      University, Ube, Yamaguchi 755-8505, Japan.
FAU - Nishimoto, Yuki
AU  - Nishimoto Y
AD  - Department of Obstetrics and Gynecology, Graduate School of Medicine, Yamaguchi 
      University, Ube, Yamaguchi 755-8505, Japan.
FAU - Kajimura, Takuya
AU  - Kajimura T
AD  - Department of Obstetrics and Gynecology, Graduate School of Medicine, Yamaguchi 
      University, Ube, Yamaguchi 755-8505, Japan.
FAU - Sueoka, Kotaro
AU  - Sueoka K
AD  - Department of Obstetrics and Gynecology, Graduate School of Medicine, Yamaguchi 
      University, Ube, Yamaguchi 755-8505, Japan.
FAU - Sugino, Norihiro
AU  - Sugino N
AD  - Department of Obstetrics and Gynecology, Graduate School of Medicine, Yamaguchi 
      University, Ube, Yamaguchi 755-8505, Japan.
LA  - eng
PT  - Journal Article
DEP - 20150903
PL  - England
TA  - Mol Clin Oncol
JT  - Molecular and clinical oncology
JID - 101613422
PMC - PMC4665986
OTO - NOTNLM
OT  - endometrial cancer
OT  - human leukocyte antigen class I heavy chain
OT  - immunohistochemistry
OT  - prognostic factors
OT  - beta2-microglobulin
EDAT- 2016/01/26 06:00
MHDA- 2016/01/26 06:01
PMCR- 2015/09/03
CRDT- 2016/01/26 06:00
PHST- 2015/03/23 00:00 [received]
PHST- 2015/05/18 00:00 [accepted]
PHST- 2016/01/26 06:00 [entrez]
PHST- 2016/01/26 06:00 [pubmed]
PHST- 2016/01/26 06:01 [medline]
PHST- 2015/09/03 00:00 [pmc-release]
AID - MCO-0-0-636 [pii]
AID - 10.3892/mco.2015.636 [doi]
PST - ppublish
SO  - Mol Clin Oncol. 2015 Nov;3(6):1285-1290. doi: 10.3892/mco.2015.636. Epub 2015 Sep 
      3.